# AD1208 in Subjects With Any Progressive, Locally Advanced or Metastatic Solid Tumors

Source: https://onco.cc/trials/nct06911333/  
OnCo record `nct06911333` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of AD1208 in advanced solid tumours, run by Avelos Therapeutics Inc., now recruiting.

## Summary

AD1208 in Subjects With Any Progressive, Locally Advanced or Metastatic Solid Tumors is a phase 1/2 interventional study registered as NCT06911333 by Avelos Therapeutics Inc., with 36 participants planned, started 2025-03-11 and due to reach its primary completion in 2029-06-30. Interventions recorded: AD1208.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT06911333
- Phase: 1/2
- Setting: A Phase I/IIa Trial of AD1208, a Cell Cycle Inhibitor/MASTL Inhibitor, as a Single Agent or a Combination in Subjects With Any Progressive, Locally Advanced(Unresectable) or Metastatic Solid Tumors
- Sponsor: Avelos Therapeutics Inc.
- Enrolled: 36

## Sources

- ClinicalTrials.gov NCT06911333: https://clinicaltrials.gov/study/NCT06911333

## Connected records

- cancers: [Metastatic cancer (cancer that has spread)](https://onco.cc/cancers/metastatic-cancer/)

---
JSON: https://onco.cc/api/v1/entities/nct06911333.json